Loading…
Insmed Incorporated is projected to rise to $129.83 by 2027, a +28% move from its current price of $101.49. INSM is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $99.56 | $101.50 | $103.49 | +0.01% |
| Aug 2 | $98.78 | $101.52 | $104.33 | +0.03% |
| Aug 3 | $98.19 | $101.53 | $104.99 | +0.04% |
| Aug 4 | $97.69 | $101.54 | $105.55 | +0.05% |
| Aug 5 | $97.26 | $101.56 | $106.05 | +0.07% |
| Aug 6 | $96.87 | $101.57 | $106.50 | +0.08% |
| Aug 7 | $96.52 | $101.58 | $106.92 | +0.09% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $96.52 | $101.58 | $106.92 | +0.09% |
| Week 2 | $94.58 | $101.68 | $109.31 | +0.19% |
| Week 3 | $93.14 | $101.77 | $111.20 | +0.28% |
| Week 4 | $91.96 | $101.87 | $112.84 | +0.37% |
| Week 5 | $90.94 | $101.96 | $114.32 | +0.47% |
| Week 6 | $90.04 | $102.06 | $115.68 | +0.56% |
| Week 7 | $89.22 | $102.15 | $116.96 | +0.65% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Insmed Incorporated is a healthcare company that develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company markets ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections and is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa.
In addition, it is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops INS1201, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as it is also developing pre-clinical research programs for gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. In addition, it provides INS1148, monoclonal antibody targeting stem cell factor called SCF248 that is in phase-2 clinical trial for the treatment of interstitial lung disease, and asthma; and INS1202, an intrathecally delivered gene therapy which is in phase 1 of clinical trial for the treatment of amyotrophic lateral sclerosis.
The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Insmed Incorporated is a healthcare company (INSM) currently priced at $103.12 per share with a market cap of $22.35B. It ranks 565 by market capitalization. The near-term trajectory is nuanced, with a neutral 2026 outlook and a broader bullish path beyond that horizon.
The 2026 forecast shows an average price of $103.12 within a range of $91.88 to $131.38, reflecting a neutral sentiment for the year.
A major floor 18.5% below — a decisive break under it would weaken the trend.
The nearest floor, 5.6% below — buyers have tended to step in here.
The nearest ceiling, 16.5% above — a clean break opens room to run.
A major ceiling 62.4% above — clearing it would confirm fresh momentum.
Key INSM support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of INSM market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $104.08 | Sell | $103.75 | Sell |
| MA 10 | $105.84 | Sell | $105.38 | Sell |
| MA 20 | $109.06 | Sell | $106.49 | Sell |
| MA 50 | $105.06 | Sell | $110.13 | Sell |
| MA 100 | $122.54 | Sell | $120.16 | Sell |
| MA 200 | $147.93 | Sell | $127.82 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 38.38 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -149.17 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.91 | Sell |
| ROC (12) | -7.83 | Sell |
| Bollinger %B (20,2) | 0.06 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 0.04 | Buy |
| Awesome (5,34) | -1.61 | Sell |
| Ultimate (7,14,28) | 18.36 | Buy |
| Momentum (10) | -5.97 | Sell |
| Aroon Osc (25) | -60.00 | Sell |
| Hull MA (9) | 102.17 | Sell |
| ADX (14) | 13.08 | Neutral |
| ATR (14) | 1.79 | Info |
The 30-day technical picture is mixed but currently bearish. RSI(14) is 40, and the stock is trading below the SMA50 of $105.17 while well below the SMA200 of $148.24. Near-term support sits at $95.52 and resistance at $118.26. The 30-day range spans from $90.60 to $117.37, indicating a tight trading band around the current price of $103.12.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $91.88 | $101.49 | $129.67 | 0% | Neutral | |
| $106.28 | $129.83 | $165.85 | +28% | Bullish | |
| $119.51 | $148.85 | $195.49 | +47% | Bullish | |
| $125.78 | $159.17 | $213.65 | +57% | Bullish | |
| $131.29 | $168.46 | $230.31 | +66% | Bullish | |
| $135.69 | $176.31 | $244.96 | +74% | Bullish | |
| $151.26 | $198.83 | $280.30 | +96% | Bullish | |
| $173.79 | $230.94 | $329.88 | +128% | Bullish | |
| $192.76 | $258.78 | $374.20 | +155% | Bullish | |
| $208.77 | $283.02 | $413.90 | +179% | Bullish | |
| $294.33 | $416.74 | $639.38 | +311% | Bullish | |
| $473.28 | $720.44 | $1,186.57 | +610% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $91.88 | $101.49 | $118.29 | +0.00% |
| August 2026 | $88.99 | $103.80 | $123.43 | +2.28% |
| September 2026 | $87.55 | $102.73 | $123.33 | -1.03% |
| October 2026 | $87.81 | $103.52 | $125.22 | +0.77% |
| November 2026 | $89.72 | $106.17 | $129.23 | +2.56% |
| December 2026 | $89.21 | $105.95 | $129.67 | -0.21% |
Click any year to see its month-by-month INSM forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Insmed Incorporated's 2026 outlook centres on $101.49, within a $91.88 to $129.67 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, INSM could reach as high as $165.85, with a base case around $129.83 and support toward $106.28 — roughly +28% from $101.49. Buyers look set to stay in control over this stretch.
Expect INSM to range from $119.51 to $195.49 through 2028. The $148.85 average target implies a +47% move from current prices. That is up +15% on the projected 2027 average. Momentum favours further upside here.
The INSM price prediction for 2029 points to an average of $159.17 (low $125.78, high $213.65) — a potential gain of +57% on today's $101.49. Buyers look set to stay in control over this stretch.
In 2030, INSM is projected to trade between $131.29 and $230.31, averaging $168.46 — a potential gain of +66% from today's $101.49. That is up +6% on the projected 2029 average. Momentum favours further upside here.
Insmed Incorporated's 2031 outlook centres on $176.31, within a $135.69 to $244.96 range. That is up +5% on the projected 2030 average. That marks a +74% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, INSM could reach as high as $280.30, with a base case around $198.83 and support toward $151.26 — roughly +96% from $101.49. Momentum favours further upside here.
Expect INSM to range from $173.79 to $329.88 through 2033. The $230.94 average target implies a +128% move from current prices. That is up +16% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The INSM price prediction for 2034 points to an average of $258.78 (low $192.76, high $374.20) — a potential gain of +155% on today's $101.49. Momentum favours further upside here.
In 2035, INSM is projected to trade between $208.77 and $413.90, averaging $283.02 — a potential gain of +179% from today's $101.49. That is up +9% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Insmed Incorporated's 2040 outlook centres on $416.74, within a $294.33 to $639.38 range. That is up +47% on the projected 2035 average. That marks a +311% change versus current levels. Momentum favours further upside here.
By 2050, INSM could reach as high as $1,186.57, with a base case around $720.44 and support toward $473.28 — roughly +610% from $101.49. Buyers look set to stay in control over this stretch.
Investing $1,000 in INSM today (≈ 9.853188 INSM) could be worth
$7,098.63
+$6,098.63 (+610%) by 2050 · US Dollar
Based on the average projected INSM price of $720.44 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in INSMwould be worth at today's price.
$1,000 invested in INSM on Jul 30, 2025 (≈ 9.507511 INSM) would be worth
$964.92
-$35.08 (-3.5%) today · 0.96× · US Dollar
Based on a INSM entry price of $105.18 vs. today's $101.49.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $107.41 | $944.88 | -5.5% |
| 1 month ago | $106.62 | $951.89 | -4.8% |
| 3 months ago | $133.26 | $761.59 | -23.8% |
| 6 months ago | $156.87 | $646.97 | -35.3% |
| 1 year ago | $105.18 | $964.92 | -3.5% |
| All time (5.0y) ago | $24.13 | $4,205.97 | +320.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our INSM forecast.
Our base-case forecast reaches $200.00 around 2033.
Implied market cap at $200.00: $43.35B
The multi-year forecast is bullish from 2027 onward, with steadily higher averages and rising ROI. For 2030 the average is $168.00 with a 62.9% ROI and a bullish sentiment. The outlook extends through 2040, where the average is $405.28 with a 293% ROI, and into 2050 with an average of $695.76 and a 574.7% ROI.
Earlier years show continued upside: 2027 avg $130.98 (ROI 27, bullish), 2028 avg $149.74 (ROI 45.2, bullish), 2029 avg $159.18 (ROI 54.4, bullish). These figures depict a rising long-term trajectory, but they are estimates and not guarantees, subject to market conditions and other factors.
Tap a question to reveal the answer.
2030 forecast: avg $168.00, min $130.69, max $230.25 with ROI 62.9 and sentiment bullish.
Yes. The 2027 forecast shows min $107.11, avg $130.98, max $167.57 with ROI 27 and sentiment bullish.
The outlook from 2027 onward is bullish with rising averages and higher ROI (2030: 62.9, 2040: 293, 2050: 574.7). These are estimates and not guarantees.
Current price: $103.12. Market cap: $22.35B.
Bearish sentiment with RSI(14) 40. SMA50 is $105.17 and SMA200 is $148.24. 30-day range: $90.60 to $117.37. Support at $95.52 and resistance at $118.26.
Insmed Incorporated Community Discussion
0Share your Insmed Incorporated price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.